Abstract
Alpha-particles are of considerable growing interest for Targeted Alpha Therapy (TAT). TAT gains more attention as new targets, chemical labeling techniques and α-particle emitters are developed but translation of TAT into the clinic has been slow, in part because of the limited availability and the short physical half-lives of some of the available α- particle emitters. This article is an up-to-date overview of the literature concerning α-emitters used for TAT of cancer. It briefly describes the nuclear characteristics, the production parameters (targets, extraction and purification), the complexation properties of these radionuclides to chelates and biological vectors and finally draws-upon the preclinical and clinical studies that have been performed over the past two decades. Radiobiology and dosimetry aspects are also presented in this paper.
Current Topics in Medicinal Chemistry
Title:Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Volume: 12 Issue: 23
Author(s): Sandrine Huclier-Markai, Cyrille Alliot, Nicolas Varmenot, Cathy S. Cutler and Jacques Barbet
Affiliation:
Keywords: 212Pb, 212Bi, 213Bi, 211At, 223Ra, 225Ac
Abstract: Alpha-particles are of considerable growing interest for Targeted Alpha Therapy (TAT). TAT gains more attention as new targets, chemical labeling techniques and α-particle emitters are developed but translation of TAT into the clinic has been slow, in part because of the limited availability and the short physical half-lives of some of the available α- particle emitters. This article is an up-to-date overview of the literature concerning α-emitters used for TAT of cancer. It briefly describes the nuclear characteristics, the production parameters (targets, extraction and purification), the complexation properties of these radionuclides to chelates and biological vectors and finally draws-upon the preclinical and clinical studies that have been performed over the past two decades. Radiobiology and dosimetry aspects are also presented in this paper.
Export Options
About this article
Cite this article as:
Huclier-Markai Sandrine, Alliot Cyrille, Varmenot Nicolas, S. Cutler Cathy and Barbet Jacques, Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics, Current Topics in Medicinal Chemistry 2012; 12 (23) . https://dx.doi.org/10.2174/1568026611212230002
DOI https://dx.doi.org/10.2174/1568026611212230002 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Therapeutic Use of Chemokines
Current Pharmaceutical Design A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Current Medicinal Chemistry Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Chemical and Bioactive Diversities of the Genus Chaetomium Secondary Metabolites
Mini-Reviews in Medicinal Chemistry Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Intraoperative Magnetic Resonance Imaging
Current Medical Imaging